ID   KCL22/SR
AC   CVCL_4V46
DR   cancercelllines; CVCL_4V46
DR   Wikidata; Q54899694
RX   PubMed=12743326;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; STI571).
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Leufs*5 (c.3261dupC) (3261_3262insC); ClinVar=VCV000089364; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro301Glnfs*44 (c.902delC); ClinVar=VCV000233908; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2091 ! KCL-22
SX   Female
AG   32Y
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 05-10-23; Version: 11
//
RX   PubMed=12743326; DOI=10.1634/stemcells.21-3-315;
RA   Ohmine K., Nagai T., Tarumoto T., Miyoshi T., Muroi K., Mano H.,
RA   Komatsu N., Takaku F., Ozawa K.;
RT   "Analysis of gene expression profiles in an imatinib-resistant cell
RT   line, KCL22/SR.";
RL   Stem Cells 21:315-321(2003).
//